CervoMed, Inc. (CRVO)
1.39
-0.06
(-4.14%)
USD |
NASDAQ |
Nov 06, 10:28
CervoMed Net Income (Quarterly) : -6.572M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.572M |
| March 31, 2026 | -7.964M |
| December 31, 2025 | -8.087M |
| September 30, 2025 | -7.727M |
| June 30, 2025 | -6.258M |
| March 31, 2025 | -4.894M |
| December 31, 2024 | -6.706M |
| September 30, 2024 | -4.754M |
| June 30, 2024 | -2.317M |
| March 31, 2024 | -2.514M |
| December 31, 2023 | -2.362M |
| September 30, 2023 | 2.150M |
| June 30, 2023 | -1.426M |
| March 31, 2023 | -0.5343M |
| December 31, 2022 | -1.527M |
| September 30, 2022 | -0.8826M |
| June 30, 2022 | -4.190M |
| March 31, 2022 | -4.527M |
| December 31, 2021 | -3.474M |
| September 30, 2021 | -12.20M |
| June 30, 2021 | -3.778M |
| March 31, 2021 | -4.644M |
| December 31, 2020 | -4.062M |
| September 30, 2020 | -4.439M |
| June 30, 2020 | -3.125M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.559M |
| December 31, 2019 | -3.752M |
| September 30, 2019 | -2.804M |
| June 30, 2019 | -2.495M |
| March 31, 2019 | -2.748M |
| December 31, 2018 | -5.571M |
| September 30, 2018 | -6.720M |
| June 30, 2018 | -2.765M |
| March 31, 2018 | -3.314M |
| December 31, 2017 | 1.790M |
| September 30, 2017 | 3.258M |
| June 30, 2017 | 9.972M |
| March 31, 2017 | -28.64M |
| December 31, 2016 | -2.571M |
| September 30, 2016 | -5.437M |
| June 30, 2016 | -3.806M |
| March 31, 2016 | -6.223M |
| December 31, 2015 | -3.110M |
| September 30, 2015 | -1.423M |
| June 30, 2015 | -3.969M |
| March 31, 2015 | -3.516M |
| December 31, 2014 | -5.068M |
| September 30, 2014 | -3.450M |
| June 30, 2014 | -4.455M |
| March 31, 2014 | -1.380M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.572M |
| EPS Diluted (Quarterly) | -0.6415 |
| Enterprise Value | -5.325M |
| Earnings Yield | -231.0% |
| Normalized Earnings Yield | -230.99 |